Heron Therapeutics, Inc.

Day range

$0.28 – $0.30

Open

$0.30

Prev close

$0.30

Volume

722.07K

Market cap

$57.49M

Shares out

189.85M

P/E

—

P/S

0.38

P/B

8.24

P/FCF

—

ROE

-492.9%

ROA

-13.5%

Debt/Equity

20.65

Div yield

0.00%

As of Oct 23, 2026

• Partnership or collaborationSep 29, 2026

  The License Agreement ... provided for ... certain obligations to collaborate on developing and commercializing such products.

• Quarterly earningsAug 10, 2026

  On August 10, 2026, Heron Therapeutics, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2026 ('Earnings Press Release').

• Listing deficiency noticeJun 25, 2026

  On June 25, 2026, Heron Therapeutics, Inc. (the "Company") received a written notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") notifying it that the closing bid price of the Company's common shares over a period of thirty (30) consecutive trading days was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) during the May 12, 2026 to June 24, 2026 period. In accordance with applicable Nasdaq procedures, the Company has been provided a period of 180 calendar days, or until December 22, 2026, to cure the deficiency and regain compliance.

• Equity compensation grantJun 16, 2026

  The Company's stockholders approved the amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional 16,560,000 shares

• Material litigationJun 2, 2026

  On January 24, 2024, the Company filed a complaint for patent infringement of the CINVANTI Orange Book patents against Slayback and a related entity in the U.S. District Court for the District of New Jersey in response to Slayback's NDA filing. On December 12, 2024, the Company filed a complaint against Slayback, Azurity, and related entities in the U.S. District Court for District of Delaware for patent infringement of U.S. Patent Nos. 12,115,254 and 12,115,255. On June 1, 2026, the District Court issued a decision holding that the asserted claims of Heron's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid.

Days to cover

17.3

Short interest

46.02M

Avg volume

2.66M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
  positiveGlobeNewswire Inc.· Oct 29, 2025
• Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
  neutralBenzinga· Oct 29, 2024
• Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR
  positiveGlobeNewswire Inc.· Sep 17, 2024
• Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
  Zacks Investment Research· Jul 2, 2024
• FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
  Zacks Investment Research· Jul 1, 2024